Drilldown: Medicines

Codeine (2)

Other values:

Search

None (48) · (multiple, generic dominant) (1) · Benzedrex (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Mu-opioid receptor agonist (4) · Potent mu-opioid receptor agonist (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

Search

None (61) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (61) · Adult: 15–60 mg every 4 hours as needed. (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)

None (61) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (61) · 360 mg/day (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)

None (61) · Oral (1) · PO (only formulation marketed in the US). (1)

None (61) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30–60 min (PO) (1)

None (60) · 4-6 hours (1) · 4–6 hours (1) · About 20 minutes (1)

None (60) · 2.5–3 hours (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1)

None (61) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (61) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not studied in human pregnancy; no approved clinical use in any population (1)

None (61) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)